RCE in Zkteco Zkbio Access Ivs

CVE-2024-1706

A vulnerability was determined in ZKTeco ZKBio Access IVS up to 3.3.2. This impacts an unknown function of the component Department Name Search Bar. This manipulation with the input <marquee>hi causes cross site scripting. Remote exploitation of the attack is possible. The exploit has been publicly disclosed and may be utilized. The vendor explains: "ZKBio Access IVS is no longer maintained and the product has been replaced by ZKBio CVAccess, it is recommended to replace it with the latest version of ZKBio CVAccess." This vulnerability only affects products that are no longer supported by the maintainer.

Vulnerability class: XSS (Cross-Site Scripting)

Published · last modified .

CVSS v3 metric

CVSS v3 base score 3.5 (Low). Vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:N/I:L/A:N.

EPSS exploit prediction

EPSS: 0.004 (35.1th percentile), scored .

Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 35th percentile — 35.1% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS trend (30 days)EPSS over the last 30 days for CVE-2024-1706: held from 0.004 to 0.004.

EPSS over last 30 days · oldest: 0.004 · newest: 0.004 · change: 0.000

Affected products

Weakness classification (CWE)

References

Frequently asked questions

What is CVE-2024-1706?
CVE-2024-1706 is a low-severity vulnerability in Zkteco Zkbio Access Ivs, classified under Cross-site Scripting. CVSS score: 3.5/10. Published 2024-02-21.
How severe is CVE-2024-1706?
Low severity. CVSS v3 base score is 3.5 out of 10.